Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer

Introduction: CDK4/6 inhibitors in combination with aromatase inhibitors (AIs) are the standard first-line treatment for hormone receptor-positive (HR+), HER2-negative (HER2−) metastatic breast cancer. Landmark trials have demonstrated a comparable progression-free survival (PFS) across CDK4/6 inhib...

Full description

Saved in:
Bibliographic Details
Main Authors: Ram Patel, John Mathews, Caroline Hamm, Swati Kulkarni, Rasna Gupta, Tarquin Opperman, John Dean Chiong, Abdullah Nasser
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Current Oncology
Subjects:
cyclin-dependent kinase inhibitors
aromatase inhibitors
metastatic breast cancer
survival analysis
real-world evidence
Online Access:https://www.mdpi.com/1718-7729/32/1/52
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/1/52

Similar Items